See more : The National Company for Glass Industries (2150.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Intercept Pharmaceuticals, Inc. (ICPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intercept Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Saxlund Group AB (publ) (SAXG.ST) Income Statement Analysis – Financial Results
- Clearmind Medicine Inc. (CMND) Income Statement Analysis – Financial Results
- Hövding Sverige AB (publ) (HOVD.ST) Income Statement Analysis – Financial Results
- BNK Financial Group Inc. (138930.KS) Income Statement Analysis – Financial Results
- tripla Co., Ltd. (5136.T) Income Statement Analysis – Financial Results
Intercept Pharmaceuticals, Inc. (ICPT)
About Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 285.71M | 363.47M | 312.69M | 252.00M | 179.80M | 130.96M | 24.95M | 2.78M | 1.74M | 1.62M | 2.45M | 1.81M | 0.00 |
| Cost of Revenue | 984.00K | 3.10M | 5.32M | 4.21M | 2.52M | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 284.73M | 360.37M | 307.37M | 247.79M | 177.29M | 129.59M | 24.95M | 2.78M | 1.74M | 1.62M | 2.45M | 1.81M | 0.00 |
| Gross Profit Ratio | 99.66% | 99.15% | 98.30% | 98.33% | 98.60% | 98.95% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 176.64M | 185.27M | 191.49M | 242.80M | 207.30M | 191.50M | 153.89M | 128.19M | 80.31M | 27.94M | 16.18M | 11.43M | 12.71M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 255.47M | 0.00 | 0.00 | 103.75M | 34.60M | 13.13M | 4.85M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -161.00 | 331.87K | 0.00 | 0.00 |
| SG&A | 176.30M | 230.86M | 332.49M | 317.42M | 255.47M | 273.70M | 273.60M | 103.75M | 34.60M | 13.13M | 5.18M | 4.21M | 3.64M |
| Other Expenses | 6.52M | 2.16M | 4.41M | 8.89M | 6.77M | 4.52M | 3.90M | 2.73M | 776.00K | 100.38K | -104.00K | 0.00 | 104.55K |
| Operating Expenses | 352.94M | 416.13M | 523.98M | 560.22M | 462.78M | 465.20M | 427.49M | 231.94M | 114.91M | 41.07M | 21.36M | 15.64M | 15.86M |
| Cost & Expenses | 353.93M | 419.23M | 529.30M | 564.43M | 465.29M | 466.57M | 427.49M | 231.94M | 114.91M | 41.07M | 21.36M | 15.64M | 15.86M |
| Interest Income | 15.51M | 47.77M | 39.80M | 33.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 61.45K | 0.00 |
| Interest Expense | 21.39M | 54.42M | 48.05M | 41.14M | 30.52M | 29.27M | 14.20M | 0.00 | 0.00 | 0.00 | 0.00 | 13.48K | 0.00 |
| Depreciation & Amortization | 6.52M | 2.16M | 4.41M | 8.89M | 4.58M | 4.60M | 3.83M | 1.69M | 442.80K | 105.68K | 201.32K | 410.60K | 479.50K |
| EBITDA | -61.70M | -53.60M | -212.20M | -303.54M | -278.72M | -331.10M | -398.63M | -226.43M | 57.66M | -10.90M | 5.71M | -14.46M | -16.06M |
| EBITDA Ratio | -21.59% | -14.75% | -67.86% | -120.45% | -155.01% | -252.83% | -1,597.67% | -8,139.07% | 3,310.10% | -672.47% | 233.52% | -801.31% | 0.00% |
| Operating Income | -68.22M | -55.76M | -216.61M | -312.43M | -285.49M | -335.61M | -402.54M | -229.16M | -113.17M | -39.45M | -18.91M | -14.88M | -16.35M |
| Operating Income Ratio | -23.88% | -15.34% | -69.27% | -123.98% | -158.78% | -256.28% | -1,613.31% | -8,237.10% | -6,496.56% | -2,432.85% | -773.25% | -824.06% | 0.00% |
| Total Other Income/Expenses | -106.64M | -35.67M | -43.64M | -32.25M | -23.75M | -24.76M | -10.29M | 2.73M | -170.06M | -28.34M | -24.73M | 0.00 | 1.27M |
| Income Before Tax | -174.86M | -91.43M | -274.88M | -344.68M | -309.24M | -360.37M | -412.83M | -226.43M | -283.23M | -67.79M | -43.64M | -13.83M | -15.09M |
| Income Before Tax Ratio | -61.20% | -25.15% | -87.91% | -136.78% | -171.99% | -275.18% | -1,654.56% | -8,139.07% | -16,258.67% | -4,180.52% | -1,784.30% | -766.17% | 0.00% |
| Income Tax Expense | -290.03M | 53.60M | 49.35M | 46.37M | 6.77M | 29.19M | 14.27M | 1.04M | 170.39M | 28.44M | 24.42M | -1.09M | -672.48K |
| Net Income | 115.17M | -145.02M | -324.23M | -391.05M | -309.24M | -360.37M | -412.83M | -226.43M | -283.23M | -67.79M | -43.64M | -12.74M | -15.09M |
| Net Income Ratio | 40.31% | -39.90% | -103.69% | -155.18% | -171.99% | -275.18% | -1,654.56% | -8,139.07% | -16,258.67% | -4,180.52% | -1,784.30% | -705.64% | 0.00% |
| EPS | 3.41 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
| EPS Diluted | 3.40 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
| Weighted Avg Shares Out | 33.82M | 31.86M | 32.97M | 31.65M | 28.46M | 25.05M | 24.66M | 23.69M | 20.78M | 18.03M | 6.28M | 3.33M | 3.33M |
| Weighted Avg Shares Out (Dil) | 33.84M | 31.89M | 32.97M | 31.65M | 28.46M | 25.05M | 24.66M | 23.69M | 20.78M | 18.03M | 6.28M | 3.33M | 3.33M |
US FDA declines full approval for Intercept's liver disease drug
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, raising questions about its future in the market.
Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)
MORRISTOWN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) that addresses the supplemental...
FDA advisers vote against confirmatory data for Intercept's liver disease drug
Independent advisers to the U.S. Food and Drug Administration voted on Friday against confirmatory trial data for Intercept Pharmaceuticals' liver disease drug, putting into question the treatment's future in the U.S. market.
FDA staff raises efficacy concerns over Intercept's liver disease drug
The U.S. Food and Drug Administration's staff on Wednesday raised concerns over the efficacy of Intercept Pharmaceuticals' liver disease drug, which is awaiting the regulator's traditional approval.
Sophos Group (OTCMKTS:SPHHF) & Loomis AB (publ) (OTCMKTS:LOIMF) Financial Review
Loomis AB (publ) (OTCMKTS:LOIMF – Get Free Report) and Sophos Group (OTCMKTS:SPHHF – Get Free Report) are both business services companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability,...
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Gilead Sciences, Inc. (GILD Quick QuoteGILD - Free Report) announced positive interim results from the ongoing ASSURE study on pipeline candidate seladelpar.ASSURE is an open-label study evaluating the long-term safety and efficacy of seladelpar, a once-daily potent and selective peroxisome...
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that...
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
BOLOGNA, Italy & MORRISTOWN, N.J.--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma's successful tender...
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.
BOLOGNA, Italy--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”) announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. (“Interstellar”), successfully completed its tender offer to purchase all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (“Intercept”), at...
Source: https://incomestatements.info
Category: Stock Reports